BioCentury
ARTICLE | Product Development

Getting to the point in IBS

How patient-focused endpoints could expand the number of patients taking Linzess

July 21, 2018 12:08 AM UTC

A large epidemiological study set Ironwood Pharmaceuticals Inc. on a path to finding symptomatic outcomes important to IBS-C patients. The company’s new Phase IIIb study of Linzess linaclotide will probe those outcomes, seeking results that could change how doctors and patients think about treatment goals.

Linzess was approved in 2012 to treat constipation-predominant irritable bowel syndrome (IBS-C) based on improvements in abdominal pain and constipation...

BCIQ Company Profiles

Ironwood Pharmaceuticals Inc.